NEW YORK, July 27, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ICU Medical, Inc. (NASDAQ:ICUI), A. Schulman, Inc. (NASDAQ:SHLM), Verso Corporation (NYSE:VRS), Eli Lilly and Company (NYSE:LLY), Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), and Intuit Inc. (NASDAQ:INTU), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

ICUI DOWNLOAD: http://Fundamental-Markets.com/register/?so=ICUI
SHLM DOWNLOAD: http://Fundamental-Markets.com/register/?so=SHLM
VRS DOWNLOAD: http://Fundamental-Markets.com/register/?so=VRS
LLY DOWNLOAD: http://Fundamental-Markets.com/register/?so=LLY
SPPI DOWNLOAD: http://Fundamental-Markets.com/register/?so=SPPI
INTU DOWNLOAD: http://Fundamental-Markets.com/register/?so=INTU

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine ICU Medical, Inc. (NASDAQ:ICUI), A. Schulman, Inc. (NASDAQ:SHLM), Verso Corporation (NYSE:VRS), Eli Lilly and Company (NYSE:LLY), Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), and Intuit Inc. (NASDAQ:INTU) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed July 25th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

ICU MEDICAL, INC. (ICUI) REPORT OVERVIEW

ICU Medical's Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, ICU Medical reported revenue of $372.03MM vs $247.74MM (up 50.17%) and basic earnings per share $0.24 vs $3.03 (down 92.08%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, ICU Medical reported revenue of $1,292.61MM vs $379.37MM (up 240.72%) and basic earnings per share $3.50 vs $3.90 (down 10.26%). ICU Medical is expected to report earnings on August 9th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was $0.52. The estimated EPS forecast for the next fiscal year is $8.61 and is expected to report on March 7th, 2019.

To read the full ICU Medical, Inc. (ICUI) report, download it here: http://Fundamental-Markets.com/register/?so=ICUI

-----------------------------------------

A. SCHULMAN, INC. (SHLM) REPORT OVERVIEW

A. Schulman's Recent Financial Performance

For the three months ended May 31st, 2018 vs May 31st, 2017, A. Schulman reported revenue of $722.24MM vs $645.80MM (up 11.84%) and basic earnings per share $0.11 vs $0.47 (down 76.60%). For the twelve months ended August 31st, 2017 vs August 31st, 2016, A. Schulman reported revenue of $2,461.12MM vs $2,496.01MM (down 1.40%) and basic earnings per share $0.87 vs -$12.44. A. Schulman is expected to report earnings on August 1st, 2018. The report will be for the fiscal period ending May 31st, 2018. The reported EPS for the same quarter last year was $0.63. The estimated EPS forecast for the next fiscal year is $2.67 and is expected to report on October 24th, 2018.

To read the full A. Schulman, Inc. (SHLM) report, download it here: http://Fundamental-Markets.com/register/?so=SHLM

-----------------------------------------

VERSO CORPORATION (VRS) REPORT OVERVIEW

Verso's Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, Verso reported revenue of $639.00MM vs $616.00MM (up 3.73%) and basic earnings per share -$0.06 vs -$0.61. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Verso reported revenue of $2,461.00MM vs $2,641.00MM (down 6.82%) and basic earnings per share -$0.87 vs $33.32. Verso is expected to report earnings on August 8th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was -$1.42. The estimated EPS forecast for the next fiscal year is $1.99 and is expected to report on March 14th, 2019.

To read the full Verso Corporation (VRS) report, download it here: http://Fundamental-Markets.com/register/?so=VRS

-----------------------------------------

ELI LILLY AND COMPANY (LLY) REPORT OVERVIEW

Eli Lilly's Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, Eli Lilly reported revenue of $5,700.00MM vs $5,228.30MM (up 9.02%) and basic earnings per share $1.16 vs -$0.10. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Eli Lilly reported revenue of $22,871.30MM vs $21,222.10MM (up 7.77%) and basic earnings per share -$0.19 vs $2.59. Eli Lilly is expected to report earnings on October 23rd, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $1.05. The estimated EPS forecast for the next fiscal year is $5.59 and is expected to report on January 30th, 2019.

To read the full Eli Lilly and Company (LLY) report, download it here: http://Fundamental-Markets.com/register/?so=LLY

-----------------------------------------

SPECTRUM PHARMACEUTICALS, INC. (SPPI) REPORT OVERVIEW

Spectrum Pharmaceuticals' Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, Spectrum Pharmaceuticals reported revenue of $30.50MM vs $29.10MM (up 4.79%) and basic earnings per share -$0.16 vs -$0.30. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Spectrum Pharmaceuticals reported revenue of $128.37MM vs $146.44MM (down 12.34%) and basic earnings per share -$1.07 vs -$0.96. Spectrum Pharmaceuticals is expected to report earnings on August 2nd, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was -$0.26. The estimated EPS forecast for the next fiscal year is -$0.75 and is expected to report on March 5th, 2019.

To read the full Spectrum Pharmaceuticals, Inc. (SPPI) report, download it here: http://Fundamental-Markets.com/register/?so=SPPI

-----------------------------------------

INTUIT INC. (INTU) REPORT OVERVIEW

Intuit's Recent Financial Performance

For the three months ended April 30th, 2018 vs April 30th, 2017, Intuit reported revenue of $2,925.00MM vs $2,541.00MM (up 15.11%) and basic earnings per share $4.68 vs $3.76 (up 24.47%). For the twelve months ended July 31st, 2017 vs July 31st, 2016, Intuit reported revenue of $5,177.00MM vs $4,694.00MM (up 10.29%) and basic earnings per share $3.78 vs $3.73 (up 1.34%). Intuit is expected to report earnings on August 28th, 2018. The report will be for the fiscal period ending July 31st, 2018. The reported EPS for the same quarter last year was $0.10. The estimated EPS forecast for the next fiscal year is $5.26 and is expected to report on August 28th, 2018.

To read the full Intuit Inc. (INTU) report, download it here: http://Fundamental-Markets.com/register/?so=INTU

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at [email protected].

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: [email protected]

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at [email protected].

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.